From: Blood volume and hemoglobin mass in long-term heart transplant recipients with and without Anemia
 | Group | p | |
---|---|---|---|
HTX | CON | ||
Sex (F, M, total n) | 7 F, 29 M, 36 | 5 F, 41 M, 46 |  |
Age (yrs) | 51.6 ± 15.3 | 52.1 ± 13.4 | 0.878 |
Height (cm) | 177.3 ± 8.0 | 178.4 ± 6.4 | 0.531 |
Weight (kg) | 83.9 ± 18.1 | 83.0 ± 10.7 | 0.773 |
BMI (kg/m2) | 26.6 ± 5.0 | 26.1 ± 3.6 | 0.676 |
BSA (m2) | 2.0 ± 0.2 | 2.0 ± 0.1 | 0.944 |
Heart rate (/min) | 84.7 ± 10.9 | – |  |
Mean arterial pressure (mmHg) | 104 ± 10.7 (n = 32) | – |  |
Ejection fraction (%), Simpson’s rule | 59.7 ± 6.7 (n = 29) | – |  |
E/e’ mean | 9.2 ± 4.1 (n = 31) |  |  |
proBNP (pg/ml) | 555 ± 525 (n = 32) | – |  |
Years since heart transplantation | 6.3 ± 4.3 | – |  |
Cause for HTX | |||
 Ischemic CM, n (%) | 9 (25) | – |  |
 Dilatative CM, n (%) | 20 (56) | – |  |
 Myocarditis, n (%) | 5 (14) | – |  |
 Other, n (%) | 2 (5) | – |  |
Medication in HTX | |||
 Calciumchannel blocker | 19 (53) |  |  |
 Beta-blocker | 8 (22) | – |  |
 Ivabradine | 1 (3) | – |  |
 ACE-inhibitor | 15 (42) | – |  |
 AT-1 antagonist | 9 (25) | – |  |
 Diuretic | 19 (53) | – |  |
 Loop diuretic | 16 (44) | – |  |
 Thiazide | 4 (11) | – |  |
 Iron supplementation | 3 (8) | – |  |
 Glucocorticoid | 3 (8) | – |  |
Immunosuppression | |||
 Everolimus / Cyclosporine | 18 (50) | – |  |
 Everolimus / Tacrolimus | 7 (19) | – |  |
 MMF / Cyclosporine | 7 (19) | – |  |
 MMF / Tacrolimus | 4 (11) | – |  |